Association of glucagon-like peptide-1 receptor agonists and seven common mental disorders: A drug target and mediation Mendelian randomization
Authors:
- 28 May 2025
- journal article
- review article
- Published by Elsevier in Journal of Affective Disorders
- Vol. 388, 119509
Abstract
No abstract availableKeywords
This publication has 63 references indexed in Scilit:
- Multiomics Insight Into the Role of Glucagon-Like Peptide-1 Receptor Agonists in Heart FailureESC Heart Failure, 2025
- Type 2 Diabetes and Its Association With Psychiatric Disorders in Young Adults in South KoreaJAMA Network Open, 2023
- Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With ObesityJAMA, 2022
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without DiabetesJAMA, 2022
- Association of Antihypertensive Drug Target Genes With Psychiatric DisordersJAMA Psychiatry, 2021
- Exenatide, a GLP‐1 analog, has healing effects on LPS‐induced autism model: Inflammation, oxidative stress, gliosis, cerebral GABA, and serotonin interactionsInternational Journal of Developmental Neuroscience, 2020
- Attention Deficit/Hyperactivity, the Metabolic Syndrome, and Type 2 DiabetesCurrent Diabetes Reports, 2019
- Obesity-Induced Cellular Senescence Drives Anxiety and Impairs NeurogenesisCell Metabolism, 2019
- Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticityBrain Research, 2018
- The neuroprotective effects of GLP-1: Possible treatments for cognitive deficits in individuals with mood disordersBehavioural Brain Research, 2013